Fac­ing fears of neu­ronal dam­age, No­var­tis slams brakes on Hunt­ing­ton's tri­al

No­var­tis has sus­pend­ed dos­ing in a Hunt­ing­ton’s dis­ease study af­ter safe­ty sig­nals emerged that point to po­ten­tial side ef­fects on pa­tients’ nerves.

Specif­i­cal­ly, the drug­mak­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER